| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| Revenue | $8.6M | +136.8% |
| R&D Expense | $53.4M | +103.7% |
| SG&A Expense | $22.3M | +115.5% |
| Operating Income | -$67.1M | -103.7% |
| Net Income | -$63.1M | -93.0% |
| EPS (Basic) | -$1.52 | -9.4% |
| EPS (Diluted) | -$1.52 | -9.4% |
| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $51.4M | +44.5% |
| Short-term Investments | $275.6M | -18.8% |
| Accounts Receivable | $0 | — |
| Current Assets | $332.4M | -11.8% |
| Total Assets | $364.0M | -4.2% |
| Current Liabilities | $16.5M | +29.0% |
| Total Liabilities | $43.3M | +220.6% |
| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$42.9M | -152.8% |
| Capital Expenditures | $6.4M | +334.9% |
| Investing Cash Flow | $58.3M | +117.1% |
| Financing Cash Flow | $500K | -99.9% |
| Free Cash Flow | -$49.4M | -167.5% |
| Stockholders' Equity |
| $320.7M |
| -12.4% |